Request for information - E60PH-28MPIV - Pandemic Influenza Vaccine Readiness and Supply Strategy

PROCUREMENT OVERVIEW:
The Government of Canada, through the Department of Public Works and Government Services (PSPC), is seeking information regarding the readiness and supply strategy for Pandemic Influenza Vaccines (PIV). The primary objective is to secure sufficient production capacity for up to 110 million doses of a monovalent PIV. This Request for Information (RFI) aims to gather insights from potential suppliers about their capabilities and interest in future contracts related to PIV readiness and supply, addressing both medium- and long-term needs.

ISSUING ORGANIZATION:
Department of Public Works and Government Services (PSPC)
Gatineau, Quebec, Canada
Primary Contacts:

• Wijaya Putri
• Yessica Karnali
  Email: [email protected]

KEY DATES:

• Posted Date: June 22, 2026
• Proposal Due Date: August 14, 2026, at 14:00
• Anticipated Award Date: Not specified
• Performance Period: Not specified

CONTRACT DETAILS:
The procurement method is competitive, with an open invitation for suppliers to submit proposals. Specific contract type and estimated value are not mentioned in the RFI.

MANDATORY REQUIREMENTS:

• Suppliers must demonstrate the ability to produce or supply monovalent PIV at the scale of 110 million doses.
• No specific certifications, registrations, or security clearances are mentioned as mandatory in the RFI.
• There are no stated geographic restrictions or set-aside requirements.
• Minimum years of experience or past performance requirements are not specified.
• Bonding or insurance requirements are not mentioned.

TECHNICAL CAPABILITIES:
Bidders should possess expertise in vaccine production and supply chain management, particularly in the context of pandemic preparedness. Familiarity with regulatory standards for vaccine development and distribution is likely essential.

DELIVERABLES AND PERFORMANCE STANDARDS:
While specific deliverables and performance metrics are not outlined in the RFI, bidders should be prepared to discuss their capacity for timely production and delivery of PIV, as well as any reporting requirements related to supply chain and production status.

EVALUATION CRITERIA:
The RFI does not specify detailed evaluation criteria or weighting factors. However, it is implied that the technical approach and capacity to meet the production requirements will be significant factors in assessing supplier responses.

PREFERRED QUALIFICATIONS:
While not mandatory, suppliers with prior experience in large-scale vaccine production, especially in pandemic scenarios, will likely have a competitive advantage. Preferred qualifications may include relevant certifications in pharmaceutical manufacturing, quality assurance, and regulatory compliance.

In summary, potential bidders should assess their capabilities in large-scale vaccine production and supply chain management, prepare to demonstrate their readiness to meet the outlined requirements, and consider any relevant experience that could enhance their proposal.